Non-healing wounds are a major health care problem, and at any given time more that 3 million Americans have chronic wounds. The overall objective of this research plan is to gain a better understanding of the molecular and cellular effect of growth factors on would repair. This research proposal is based on the hypothesis that wound repair can be accelerated if one can: 1) specifically deliver certain growth factor genes into the wound microenvironment; 2) optimize their level of expression; and 3) optimize the timing of expression. Wounds in aged pigs are studied because pig skin is similar to human skin and delayed or absent healing is more common in the elderly. This research plan contains a combination of three new concepts for promoting wound healing. First is the use of a sealed chamber to cover the wound, creating an incubator environment. With use of this model, the wound micro-environment can readily be modified in a specific fashion like a tissue culture in vivo. Secondly, the wound healing process is modulated by targeting delivery of growth factor genes into the wound microenvironment using in vivo microseeding gene transfer. This method yields much higher levels of gene expression than gene transfer mediated by particle-bombardment or single injection. Because gene transfer offers targeted local and persistent delivery of therapeutic polypeptides, a single genetic intervention should be sufficient to adequately promote wound repair. Thirdly, as roles of different growth factors may differ at various stages of the healing process and uncontrolled expression of growth factors may delay healing, the production of exogenous growth factors in the wound will be turned on and off with a tetracycline-regulated genetic switch. With this switch, the timing and therapeutic levels of growth-promoting gene expression can be precisely controlled, maximizing the biological effect of the growth factors delivered. Therefore, the expression of exogenous growth factors can be easily regulated to complement the endogenous profile. Moreover, with a switch that allows precise timing of expression, the role of specific growth factors at each individual stage of healing can be elucidated.
In Specific Aim One, we will attempt to increase the rate of healing by up- regulating growth factors in the wound environment by microseeding gene transfer. The Second and Third Specific Aims will combine in vivo and ex vivo gene transfer with the tetracycline-reversible genetic switch developed in our laboratory. When proven effective in pigs, these methodologies could be used in patients with non-healing wounds. To our knowledge this is also the safest system available for in vivo and ex vivo gene delivery to skin, offering therapeutic potential for other skin diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM051449-08
Application #
6636104
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Program Officer
Ikeda, Richard A
Project Start
1995-08-01
Project End
2005-02-28
Budget Start
2003-03-01
Budget End
2005-02-28
Support Year
8
Fiscal Year
2003
Total Cost
$341,490
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Hackl, Florian; Bergmann, Juri; Granter, Scott R et al. (2012) Epidermal regeneration by micrograft transplantation with immediate 100-fold expansion. Plast Reconstr Surg 129:443e-452e
Koyama, Taro; Hackl, Florian; Aflaki, Pejman et al. (2011) A new technique of ex vivo gene delivery of VEGF to wounds using genetically modified skin particles promotes wound angiogenesis. J Am Coll Surg 212:340-8
Zuhaili, Baraa; Aflaki, Pejman; Koyama, Taro et al. (2010) Meshed skin grafts placed upside down can take if desiccation is prevented. Plast Reconstr Surg 125:855-65
Lu, Zheming; Brans, Richard; Akhrameyeva, Natali V et al. (2009) High-level expression of glycoprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection. J Invest Dermatol 129:1174-84
Brans, Richard; Eriksson, Elof; Yao, Feng (2008) Immunization with a dominant-negative recombinant HSV type 1 protects against HSV-1 skin disease in guinea pigs. J Invest Dermatol 128:2825-32
Hirsch, Tobias; Spielmann, Malte; Velander, Patrik et al. (2008) Insulin-like growth factor-1 gene therapy and cell transplantation in diabetic wounds. J Gene Med 10:1247-52
Yao, Feng; Pomahac, Bohdan; Visovatti, Scott et al. (2007) Systemic and localized reversible regulation of transgene expression by tetracycline with tetR-mediated transcription repression switch. J Surg Res 138:267-74
Vranckx, Jan Jeroen; Hoeller, Daniela; Velander, Patrik E M et al. (2007) Cell suspension cultures of allogenic keratinocytes are efficient carriers for ex vivo gene transfer and accelerate the healing of full-thickness skin wounds by overexpression of human epidermal growth factor. Wound Repair Regen 15:657-64
Yao, Feng; Theopold, Christoph; Hoeller, Daniela et al. (2006) Highly efficient regulation of gene expression by tetracycline in a replication-defective herpes simplex viral vector. Mol Ther 13:1133-41
Augustinova, Hanka; Hoeller, Daniela; Yao, Feng (2004) The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice. J Virol 78:5756-65

Showing the most recent 10 out of 19 publications